Exceptional Glycemic Control With Very Low-Carbohydrate Diet

Share this content:
Exceptional Glycemic Control With Very Low-Carbohydrate Diet
Exceptional Glycemic Control With Very Low-Carbohydrate Diet

TUESDAY, May 8, 2018 (HealthDay News) -- For children and adults with type 1 diabetes mellitus (T1DM), consuming a very low-carbohydrate diet (VLCD) is associated with exceptional glycemic control, according to a study published online May 7 in Pediatrics.

Belinda S. Lennerz, M.D., Ph.D., from Boston Children's Hospital, and colleagues surveyed adults with T1DM who followed a VLCD and parents of children who did so. The respondents were part of an international social media group. Current hemoglobin A1c (HbA1c), change in HbA1c, total daily insulin dose, and adverse events were assessed among 316 respondents, 42 percent of whom were parents of children with T1DM.

The researchers obtained suggestive evidence of T1DM for 273 respondents (86 percent). The mean age at diagnosis was 16±14 years, and duration of diabetes was 11±13 years. Participants had followed a VLCD for a mean of 2.2±3.9 years; the mean daily carbohydrate intake was 36±15 g. The mean HbA1c was 5.67±0.66 percent. In the past year, only 2 percent of respondents reported diabetes-related hospitalizations, including 1 percent each for ketoacidosis and hypoglycemia.

"Exceptional glycemic control of T1DM with low rates of adverse events was reported by a community of children and adults who consume a VLCD," the authors write. "The generalizability of these findings required further studies, including high-quality randomized controlled trials."

Some authors reported receiving royalties from books related to diabetes management; several authors disclosed financial ties to pharmaceutical and diet companies.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths